Table 1. Patients' characteristics at cancer diagnosis.
| Variable | Categories | ADCs (n = 435) | NADCs (n = 431) | Overall (n = 866) | P-value |
| Death, n (%) | 142 (33) | 166 (38) | 308 (36) | 0.071 | |
| Gender, n (%) | 0.372 | ||||
| Male | 345 (79) | 331 (77) | 676 (78) | ||
| Female | 90 (21) | 100 (23) | 190 (22) | ||
| Age at cancer diagnosis, years, n (%) | <0.001 | ||||
| 18–34 | 82 (19) | 36 (8) | 118 (14) | ||
| 35–49 | 258 (59) | 251 (58) | 509 (59) | ||
| ≥50 | 95 (22) | 144 (33) | 239 (27) | ||
| HIV risk factor, n (%) | 0.001 | ||||
| IVDU | 140 (32) | 185 (43) | 325 (38) | ||
| other | 295 (68) | 246 (57) | 541 (62) | ||
| HCV or HBV co-infection, n (%) | 183 (42) | 238 (55) | 421 (49) | <0.001 | |
| Previous AIDS event, n (%) | 184 (42) | 183 (42) | 367 (42) | 0.962 | |
| CD4 cell count at cancer diagnosis, cell/mm3 | <0.001 | ||||
| ≥200 | 203 (46) | 310 (72) | 513 (59) | ||
| <200 | 181 (42) | 103 (24) | 284 (33) | ||
| missing | 51 (12) | 18 (4) | 69 (8) | ||
| Nadir Cd4, cell/mm3, n(%) | <0.001 | ||||
| ≥200 | 113 (26) | 176 (41) | 289 (33) | ||
| 100–199 | 187 (43) | 170 (39) | 357 (41) | ||
| <50 | 135 (31) | 85 (20) | 220 (26) | ||
| Antiretroviral therapy, n (%) | 0.007 | ||||
| No cART | 80 (18) | 51 (12) | 131 (15) | ||
| cART | 355 (82) | 380 (88) | 735 (85) | ||
| HIVRNA, copies/mL, n (%) | <0.001 | ||||
| Undetectable | 107 (25) | 198 (46) | 305 (36) | ||
| Positive | 267 (61) | 213 (49) | 480 (55) | ||
| missing | 61 (14) | 20 (5) | 81 (9) | ||
| Median age at diagnosis (IQR) | 42 (36–48) | 48 (41–54) | 44 (38–50) | <0.001 | |
| Median CD4 cell count (IQR) | 214(85–409) | 349 (200–498) | 291 (133–457) | <0.001 | |
| Median HIVRNA, copies/mL | 657 (37–21000) | 70 (37–4300) | 301 (37–9400) | <0.001 |
Note: ADCs: AIDS-defining cancers, NADCs: Non-AIDS-defining cancers, IVDU: injection drug users, HBV: hepatitis B virus, HCV: hepatitis C virus, cART: combined antiretroviral therapy.